Real-time Estimate
Cboe BZX
11:59:57 2024-05-02 am EDT
|
5-day change
|
1st Jan Change
|
26.72
USD
|
-4.28%
|
|
+1.43%
|
-15.81%
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
164.5
|
1,122
|
975.6
|
450.4
|
842.6
|
751.6
|
-
|
-
|
Enterprise Value (EV)
1 |
164.5
|
672.7
|
668.2
|
149.4
|
576.5
|
387.7
|
751.6
|
751.6
|
P/E ratio
|
-5.06
x
|
-12.2
x
|
-4.78
x
|
48.5
x
|
-31.5
x
|
-10.7
x
|
-161
x
|
4.86
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
7.92
x
|
118
x
|
78.9
x
|
2.19
x
|
4.96
x
|
5.11
x
|
3.12
x
|
1.49
x
|
EV / Revenue
|
7.92
x
|
70.5
x
|
54.1
x
|
0.73
x
|
3.39
x
|
2.64
x
|
3.12
x
|
1.49
x
|
EV / EBITDA
|
-
|
-
|
-3.31
x
|
10.9
x
|
-7.99
x
|
-10.7
x
|
-12.4
x
|
-
|
EV / FCF
|
-
|
-15,081,355
x
|
-2,827,861
x
|
-
|
-
|
-
|
-5,502,358
x
|
-9,283,582
x
|
FCF Yield
|
-
|
-0%
|
-0%
|
-
|
-
|
-
|
-0%
|
-0%
|
Price to Book
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Nbr of stocks (in thousands)
|
15,138
|
25,858
|
26,361
|
26,555
|
26,723
|
26,928
|
-
|
-
|
Reference price
2 |
10.87
|
43.38
|
37.01
|
16.96
|
31.53
|
27.91
|
27.91
|
27.91
|
Announcement Date
|
3/11/20
|
3/1/21
|
2/28/22
|
3/28/23
|
3/7/24
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
20.79
|
9.539
|
12.36
|
206
|
169.9
|
147
|
241.1
|
503.3
|
EBITDA
1 |
-
|
-
|
-201.7
|
13.7
|
-72.11
|
-36.2
|
-60.49
|
-
|
EBIT
1 |
-25.51
|
-71.52
|
-202.9
|
12.18
|
-75.07
|
-78.56
|
-5.063
|
231
|
Operating Margin
|
-122.72%
|
-749.81%
|
-1,641.33%
|
5.91%
|
-44.18%
|
-53.43%
|
-2.1%
|
45.89%
|
Earnings before Tax (EBT)
1 |
-25.99
|
-72.15
|
-203.7
|
10.64
|
-24.76
|
-67.88
|
14.62
|
234.9
|
Net income
1 |
-25.99
|
-72.15
|
-203.7
|
9.349
|
-26.59
|
-68.28
|
3.499
|
157.6
|
Net margin
|
-125.02%
|
-756.35%
|
-1,647.98%
|
4.54%
|
-15.65%
|
-46.44%
|
1.45%
|
31.32%
|
EPS
2 |
-2.150
|
-3.550
|
-7.740
|
0.3500
|
-1.000
|
-2.609
|
-0.1729
|
5.740
|
Free Cash Flow
|
-
|
-44.6
|
-236.3
|
-
|
-
|
-
|
-136.6
|
-80.96
|
FCF margin
|
-
|
-467.59%
|
-1,911.95%
|
-
|
-
|
-
|
-56.66%
|
-16.08%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
2 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
3/11/20
|
3/1/21
|
2/28/22
|
3/28/23
|
3/7/24
|
-
|
-
|
-
|
Fiscal Period: December |
2021 Q3
|
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
2025 Q1
|
---|
Net sales
1 |
2.437
|
5.794
|
5.244
|
27.09
|
13.37
|
160.3
|
80.28
|
10.52
|
45.14
|
33.99
|
17.67
|
26.14
|
48.73
|
57.05
|
74.66
|
EBITDA
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-14.32
|
-43.77
|
-18.67
|
-19.81
|
-
|
-
|
EBIT
1 |
-53.82
|
-37.64
|
-50.38
|
-22.09
|
-36.81
|
121.5
|
14.76
|
-55.37
|
-19.31
|
-15.14
|
-37.8
|
-27.85
|
-10.88
|
-3.89
|
8.241
|
Operating Margin
|
-2,208.49%
|
-649.72%
|
-960.7%
|
-81.53%
|
-275.32%
|
75.77%
|
18.38%
|
-526.42%
|
-42.79%
|
-44.54%
|
-213.9%
|
-106.55%
|
-22.32%
|
-6.82%
|
11.04%
|
Earnings before Tax (EBT)
1 |
-54.08
|
-38.66
|
-51.17
|
-21.56
|
-35.27
|
118.6
|
50.86
|
-51.97
|
-15.33
|
-8.311
|
-34.65
|
-26.79
|
-7.33
|
-1.586
|
8.091
|
Net income
1 |
-54.08
|
-38.66
|
-51.17
|
-21.56
|
-35.27
|
117.3
|
50.75
|
-52.55
|
-16.22
|
-8.573
|
-32.83
|
-27.07
|
-8.073
|
-2.73
|
1.075
|
Net margin
|
-2,219.29%
|
-667.31%
|
-975.76%
|
-79.59%
|
-263.79%
|
73.21%
|
63.22%
|
-499.57%
|
-35.94%
|
-25.22%
|
-185.75%
|
-103.54%
|
-16.57%
|
-4.79%
|
1.44%
|
EPS
2 |
-2.050
|
-1.470
|
-1.940
|
-0.8200
|
-1.330
|
4.330
|
1.870
|
-1.980
|
-0.6100
|
-0.3200
|
-1.228
|
-0.9608
|
-0.2189
|
0.0250
|
0.005000
|
Dividend per Share
2 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
11/8/21
|
2/28/22
|
5/9/22
|
8/9/22
|
11/9/22
|
3/28/23
|
5/9/23
|
8/7/23
|
11/14/23
|
3/7/24
|
-
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
1 |
-
|
449
|
307
|
301
|
266
|
364
|
-
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
|
-
|
-44.6
|
-236
|
-
|
-
|
-
|
-137
|
-81
|
ROE (net income / shareholders' equity)
|
-
|
-
|
-65.2%
|
3.75%
|
-9.64%
|
-47.7%
|
-68%
|
-
|
ROA (Net income/ Total Assets)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Assets
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Book Value Per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Cash Flow per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capex
1 |
0.82
|
1.74
|
-
|
7.73
|
2.9
|
8
|
6.61
|
7.17
|
Capex / Sales
|
3.93%
|
18.26%
|
-
|
3.75%
|
1.71%
|
5.44%
|
2.74%
|
1.42%
|
Announcement Date
|
3/11/20
|
3/1/21
|
2/28/22
|
3/28/23
|
3/7/24
|
-
|
-
|
-
|
Last Close Price
27.91
USD Average target price
67.89
USD Spread / Average Target +143.24% Consensus |
1st Jan change
|
Capi.
|
---|
| -11.48% | 752M | | +0.67% | 42.4B | | +46.34% | 40.04B | | -6.20% | 28.31B | | +6.55% | 24.94B | | -21.66% | 18.96B | | +29.96% | 12.3B | | -1.57% | 11.95B | | +16.03% | 11.32B | | -4.80% | 11.55B |
Other Biotechnology & Medical Research
|